EN | UA
EN | UA

Help Support

Back

Safety and efficacy of new Vonoprazan-based regimen for H. pylori elimination

H. pylori management H. pylori management
H. pylori management H. pylori management

This single-center, prospective, randomized clinical trial sought to compare the safety and effectiveness of a new Vonoprazan-based regimen with the Bismuth-based quadruple regimen for H. pylori management.

See All

Key take away

The Vonoprazan-based regimen exhibited comparable efficacy as the Bismuth-based quadruple regimen in H. pylori-infected people.

Background

This single-center, prospective, randomized clinical trial sought to compare the safety and effectiveness of a new Vonoprazan-based regimen with the Bismuth-based quadruple regimen for H. pylori management.

Method

Patients with H. pylori who were treatment-naive were randomly allocated to either the BASE group (220 mg Bismuth two times a day, 1000 mg Amoxicillin, 500 mg Clarithromycin, and 20 mg Esomeprazole) for fourteen days, or the VAS group (Vonoprazan 20 mg two times a day, Amoxicillin 750 mg thrice a day, and S. boulardii 250 mg two times a day) for ten days. At least 4 weeks following therapy, a 13C-urea breath test was utilized to evaluate the elimination success, and adverse events were noted. Cost-effectiveness evaluations and factors related to eradication success were also carried out.

Result

After 135 people were screened, 126 were randomly selected. Table 1 displays the eradication rates for the VAS and BACE groups using both per-protocol analysis and intention-to-treat analysis. In contrast to the VAS group, the BACE group experienced a much greater rate of adverse events. The VAS group's cost-effectiveness ratio was lower than the BACE group's.

In the VAS group, non-smokers (eradication rate: 92.9% in non-smokers vs. 42.9% in smokers) and patients with a small body surface area (BSA) (eradication rate: 92.2% in people with BSA less than 1.831 vs. 66.7% in patients with BSA ≥ 1.831) were more likely to experience successful H. pylori eradication.

Conclusion

For H. pylori management, the Vonoprazan-based regimen is as efficient as the Bismuth-based quadruple regimen. It is more cost-effective, has fewer side effects, and is better suited to people with low BSA and who do not smoke.

Source:

Gut

Article:

IDDF2022-ABS-0149 Effectiveness and safety of novel Vonoprazan-based regimen for H. pylori eradication in china: a single-centre, prospective, randomized trial

Authors:

Xiaoyong Wang et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: